GRAIL, Inc. $GRAL Shares Sold by Cwm LLC

Cwm LLC lowered its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 55.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 13,840 shares of the company’s stock after selling 17,399 shares during the period. Cwm LLC’s holdings in GRAIL were worth $818,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Exchange Traded Concepts LLC grew its holdings in GRAIL by 15.4% during the third quarter. Exchange Traded Concepts LLC now owns 16,248 shares of the company’s stock worth $961,000 after acquiring an additional 2,163 shares during the period. Sheets Smith Investment Management purchased a new stake in GRAIL in the 3rd quarter worth approximately $1,689,000. NWF Advisory Services Inc. purchased a new stake in GRAIL in the 2nd quarter worth approximately $1,062,000. Reynders McVeigh Capital Management LLC grew its stake in shares of GRAIL by 4.7% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 108,255 shares of the company’s stock worth $5,566,000 after purchasing an additional 4,892 shares during the period. Finally, Osaic Holdings Inc. increased its holdings in shares of GRAIL by 33.7% during the 2nd quarter. Osaic Holdings Inc. now owns 8,880 shares of the company’s stock valued at $456,000 after purchasing an additional 2,240 shares in the last quarter.

Insider Transactions at GRAIL

In other news, CEO Robert P. Ragusa sold 7,239 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total value of $498,622.32. Following the transaction, the chief executive officer directly owned 727,388 shares of the company’s stock, valued at approximately $50,102,485.44. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Joshua J. Ofman sold 6,114 shares of the business’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $82.01, for a total transaction of $501,409.14. Following the transaction, the president owned 381,818 shares in the company, valued at $31,312,894.18. The trade was a 1.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 22,218 shares of company stock valued at $1,674,037 over the last quarter. Company insiders own 1.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GRAL shares. Morgan Stanley increased their price target on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Guggenheim upgraded GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Wednesday, November 12th. UBS Group set a $75.00 price target on GRAIL in a research note on Friday, October 3rd. Finally, Canaccord Genuity Group increased their price target on GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $97.50.

GRAIL Price Performance

NASDAQ GRAL opened at $103.59 on Thursday. GRAIL, Inc. has a 1-year low of $16.56 and a 1-year high of $115.76. The company has a market cap of $4.04 billion, a PE ratio of -8.91 and a beta of 4.52. The stock’s 50 day simple moving average is $92.35 and its 200-day simple moving average is $63.05.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, topping the consensus estimate of ($3.40) by $0.94. The firm had revenue of $36.19 million during the quarter, compared to analysts’ expectations of $33.83 million. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%. On average, equities research analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.